VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Eligible patients must meet the following criteria │ Eligible patients must meet the following criteria │     100 │
│ to be enrolled in the study                        │ to be enrolled in the study                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Newly diagnosed, stage IV squamous cell lung       │ Newly diagnosed, stage IV squamous cell lung       │     100 │
│ cancer. This includes patients who present with    │ cancer. This includes patients who present with    │         │
│ disseminated metastases, and those with a          │ disseminated metastases, and those with a          │         │
│ malignant pleural or pericardial effusion (i.e.,   │ malignant pleural or pericardial effusion (i.e.,   │         │
│ formerly stage IIIB in the 6th TNM staging system) │ formerly stage IIIB in the 6th TNM staging system) │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who have received prior adjuvant therapy  │ Patients who have received prior adjuvant therapy  │     100 │
│ for early-stage lung cancer are eligible if at     │ for early-stage lung cancer are eligible if at     │         │
│ least 12 months have elapsed from that treatment   │ least 12 months have elapsed from that treatment   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Histologically confirmed squamous cell             │ Histologically confirmed squamous cell             │     100 │
│ bronchogenic carcinoma. Patients whose tumors      │ bronchogenic carcinoma. Patients whose tumors      │         │
│ contain mixed non-small cell histologies are       │ contain mixed non-small cell histologies are       │         │
│ eligible, as long as squamous carcinoma is the     │ eligible, as long as squamous carcinoma is the     │         │
│ predominant histology. Mixed tumors with small     │ predominant histology. Mixed tumors with small     │         │
│ cell anaplastic elements are not eligible.         │ cell anaplastic elements are not eligible.         │         │
│ Cytologic specimens obtained by brushings,         │ Cytologic specimens obtained by brushings,         │         │
│ washings, or needle aspiration of the defined      │ washings, or needle aspiration of the defined      │         │
│ lesion are acceptable                              │ lesion are acceptable                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with previous radiotherapy as definitive  │ Patients with previous radiotherapy as definitive  │     100 │
│ therapy for locally advanced non-small cell lung   │ therapy for locally advanced non-small cell lung   │         │
│ cancer are eligible, as long as the recurrence is  │ cancer are eligible, as long as the recurrence is  │         │
│ outside the original radiation therapy port.       │ outside the original radiation therapy port.       │         │
│ Radiation therapy must have been completed \>4     │ Radiation therapy must have been completed >4      │         │
│ weeks prior to the initiation of study treatment.  │ weeks prior to the initiation of study treatment.  │         │
│ Patients who have received chemo/radiation for     │ Patients who have received chemo/radiation for     │         │
│ locally advanced NSCLC are not eligible. Patients  │ locally advanced NSCLC are not eligible. Patients  │         │
│ who have received palliative radiation therapy for │ who have received palliative radiation therapy for │         │
│ symptomatic metastases must have completed         │ symptomatic metastases must have completed         │         │
│ treatment \>14 days prior the initiation of the    │ treatment >14 days prior the initiation of the     │         │
│ study treatment                                    │ study treatment                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of evaluable (measureable or non-         │ Presence of evaluable (measureable or non-         │     100 │
│ measurable) disease                                │ measurable) disease                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ECOG Performance Status of 0 or 1                  │ ECOG Performance Status of 0 or 1                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Laboratory values as follows                       │ Laboratory values as follows                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hemoglobin \>9 g/dL (Note: Patients may be         │ Hemoglobin >9 g/dL (Note: Patients may be          │     100 │
│ transfused or receive erythropoietin to maintain   │ transfused or receive erythropoietin to maintain   │         │
│ or exceed this level)                              │ or exceed this level)                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Alanine aminotransferase (ALT) and aspartate       │ Alanine aminotransferase (ALT) and aspartate       │     100 │
│ aminotransferase (AST) ≤2.5 times the upper limit  │ aminotransferase (AST) ≤2.5 times the upper limit  │         │
│ of normal if no liver involvement or ≤5 times the  │ of normal if no liver involvement or ≤5 times the  │         │
│ upper limit of normal with liver involvement       │ upper limit of normal with liver involvement       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women of childbearing potential must have a        │ Women of childbearing potential must have a        │     100 │
│ negative serum pregnancy test performed within 7   │ negative serum pregnancy test performed within 7   │         │
│ days prior to start of treatment. Women of         │ days prior to start of treatment. Women of         │         │
│ childbearing potential or men with partners of     │ childbearing potential or men with partners of     │         │
│ childbearing potential must use effective birth    │ childbearing potential must use effective birth    │         │
│ control measures during treatment and at least 6   │ control measures during treatment and at least 6   │         │
│ months after the last dose of the study treatment. │ months after the last dose of the study treatment. │         │
│ If a woman becomes pregnant or suspects she is     │ If a woman becomes pregnant or suspects she is     │         │
│ pregnant while participating in this study, she    │ pregnant while participating in this study, she    │         │
│ must agree to inform her treating physician        │ must agree to inform her treating physician        │         │
│ immediately. Sexually active men must agree to use │ immediately. Sexually active men must agree to use │         │
│ a medically acceptable form of birth control       │ a medically acceptable form of birth control       │         │
│ during treatment and at least 6 months after the   │ during treatment and at least 6 months after the   │         │
│ last dose. If a female partner becomes pregnant    │ last dose. If a female partner becomes pregnant    │         │
│ during the course of the study the treating        │ during the course of the study the treating        │         │
│ physician should be informed immediately           │ physician should be informed immediately           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ability to understand the nature of this study,    │ Ability to understand the nature of this study,    │     100 │
│ give written informed consent, and comply with     │ give written informed consent, and comply with     │         │
│ study requirements                                 │ study requirements                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients entering this study must be willing to    │ Patients entering this study must be willing to    │     100 │
│ provide tissue from a previous tumor biopsy (if    │ provide tissue from a previous tumor biopsy (if    │         │
│ available) for correlative testing. An exception   │ available) for correlative testing. An exception   │         │
│ to this is when the national/local regulations     │ to this is when the national/local regulations     │         │
│ prohibits some of the key activities of this       │ prohibits some of the key activities of this       │         │
│ research like the export of samples to third       │ research like the export of samples to third       │         │
│ countries, storage of coded samples or global gene │ countries, storage of coded samples or global gene │         │
│ expression profiling without a pre-specified list  │ expression profiling without a pre-specified list  │         │
│ of target genes. If tissue is not available, a     │ of target genes. If tissue is not available, a     │         │
│ patient will still be eligible for enrollment into │ patient will still be eligible for enrollment into │         │
│ the study                                          │ the study                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior treatment with gemcitabine, carboplatin      │ Prior treatment with gemcitabine, carboplatin      │     100 │
│ (except in the adjuvant setting), or Iniparib      │ (except in the adjuvant setting), or Iniparib      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Past or current history of neoplasm other than the │ Past or current history of neoplasm other than the │     100 │
│ entry diagnosis, with the exception of treated     │ entry diagnosis, with the exception of treated     │         │
│ non-melanoma skin cancer or carcinoma in-situ of   │ non-melanoma skin cancer or carcinoma in-situ of   │         │
│ any primary site, or invasive cancers treated      │ any primary site, or invasive cancers treated      │         │
│ definitively, with treatment ending \>5 years      │ definitively, with treatment ending >5 years       │         │
│ previously and no evidence of recurrences          │ previously and no evidence of recurrences          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A history of cardiac disease, as defined by        │ A history of cardiac disease, as defined by        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Malignant hypertension                             │ Malignant hypertension                             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unstable angina                                    │ Unstable angina                                    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Congestive heart failure                           │ Congestive heart failure                           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Myocardial infarction within the previous 6 months │ Myocardial infarction within the previous 6 months │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Symptomatic, unstable or uncontrolled, cardiac     │ Symptomatic, unstable or uncontrolled, cardiac     │     100 │
│ arrhythmias. Patients who have stable, rate-       │ arrhythmias. Patients who have stable, rate-       │         │
│ controlled atrial fibrillation are eligible for    │ controlled atrial fibrillation are eligible for    │         │
│ study enrollment                                   │ study enrollment                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active brain metastases. Patients with treated     │ Active brain metastases. Patients with treated     │     100 │
│ brain metastases are eligible, if (1) radiation    │ brain metastases are eligible, if (1) radiation    │         │
│ therapy was completed at least 2 weeks prior to    │ therapy was completed at least 2 weeks prior to    │         │
│ study entry; (2) follow-up scan shows no disease   │ study entry; (2) follow-up scan shows no disease   │         │
│ progression; and (3) patient does not require      │ progression; and (3) patient does not require      │         │
│ steroids                                           │ steroids                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women who are pregnant or lactating                │ Women who are pregnant or lactating                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A serious underlying medical condition that would  │ A serious underlying medical condition that would  │     100 │
│ impair the ability of the patient to receive       │ impair the ability of the patient to receive       │         │
│ protocol treatment                                 │ protocol treatment                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A major surgical procedure, or significant         │ A major surgical procedure, or significant         │     100 │
│ traumatic injury ≤28 days of beginning treatment,  │ traumatic injury ≤28 days of beginning treatment,  │         │
│ or anticipation of the need for major surgery      │ or anticipation of the need for major surgery      │         │
│ during the course of the study                     │ during the course of the study                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Uncontrolled or intercurrent illness including,    │ Uncontrolled or intercurrent illness including,    │     100 │
│ that in the opinion of the investigator may        │ that in the opinion of the investigator may        │         │
│ increase the risks associated with study           │ increase the risks associated with study           │         │
│ participation or administration of the             │ participation or administration of the             │         │
│ investigational products, or that may interfere    │ investigational products, or that may interfere    │         │
│ with the interpretation of the results             │ with the interpretation of the results             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of any medical or psychiatric condition or │ History of any medical or psychiatric condition or │     100 │
│ laboratory abnormality that, in the opinion of the │ laboratory abnormality that, in the opinion of the │         │
│ investigator, may increase the risks associated    │ investigator, may increase the risks associated    │         │
│ with the study participation or administration of  │ with the study participation or administration of  │         │
│ the investigational products, or that may          │ the investigational products, or that may          │         │
│ interfere with the interpretation of the results   │ interfere with the interpretation of the results   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known or suspected allergy/hypersensitivity to any │ Known or suspected allergy/hypersensitivity to any │     100 │
│ agent given in the course of this trial            │ agent given in the course of this trial            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The above information is not intended to contain   │ The above information is not intended to contain   │     100 │
│ all considerations relevant to a patient's         │ all considerations relevant to a patient's         │         │
│ potential participation in a clinical trial        │ potential participation in a clinical trial        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Bilirubin \< ULN                                   │ Bilirubin < ULN                                    │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ \>18 years of age                                  │ >18 years of age                                   │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Absolute neutrophil count (ANC) \>1,500/microL and │ Absolute neutrophil count (ANC) >1,500/microL and  │      99 │
│ platelets \>100,000/microL (≤72 hours prior to     │ platelets >100,000/microL (≤72 hours prior to      │         │
│ initial treatment)                                 │ initial treatment)                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Creatinine \<2.0 mg/dL, or creatinine clearance    │ Creatinine <2.0 mg/dL, or creatinine clearance >40 │      99 │
│ \>40 mL/min (as calculated by the Cockcroft-Gault  │ mL/min (as calculated by the Cockcroft-Gault       │         │
│ method                                             │ method                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any serious, active infection (\> Grade 2) at the  │ Any serious, active infection (> Grade 2) at the   │      99 │
│ time of treatment                                  │ time of treatment                                  │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                    │   Score │
╞═══════════════════════════════════╪══════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Any serious, active infection (> Grade 2) at the │      38 │
│                                   │ time of treatment                                │         │
╘═══════════════════════════════════╧══════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 100
Average Levenshtein Ratio of individual lines: 97.97142857142858
OverAll Ratio: 98.9857142857143
